Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus

Raynell Lang1,2, Elizabeth Humes2, Brenna Hogan2

  • 1Department of Medicine University of Calgary Calgary Alberta Canada.

Insights

Hepatitis C virus (HCV) coinfection does not increase the risk of type 1 myocardial infarction (T1MI) in people with HIV (PWH). However, the risk of T1MI rises with age, particularly in PWH with HCV coinfection.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • People with HIV (PWH) face elevated cardiovascular disease (CVD) risk.
  • The specific impact of hepatitis C virus (HCV) coinfection on CVD risk in PWH remains unclear.

Purpose of the Study:

  • To investigate if HCV coinfection elevates the risk of type 1 myocardial infarction (T1MI) in PWH.
  • To determine if this risk differs based on patient age.

Main Methods:

  • Utilized data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) between 2000 and 2017.
  • Analyzed data from 23,361 PWH aged 40-79 initiating antiretroviral therapy, focusing on adjudicated T1MI events.
  • Employed discrete time-to-event analyses to estimate adjusted hazard ratios for T1MI in relation to HCV coinfection and age.

Main Results:

  • HCV coinfection was not significantly associated with an increased risk of T1MI in PWH (aHR, 0.98; 95% CI, 0.74-1.30).
  • The risk of T1MI increased with age in all PWH.
  • This age-related risk was significantly amplified in individuals with HCV coinfection (aHR per 10-year age increase, 1.85) compared to those without HCV (aHR per 10-year age increase, 1.30).

Conclusions:

  • HCV coinfection alone does not significantly increase T1MI risk in PWH.
  • Age is a significant risk factor for T1MI in PWH, and this risk is exacerbated by HCV coinfection.
  • HCV status is a crucial factor to consider when assessing CVD risk in aging PWH.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
433
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.5K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
47
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
192
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27